338 related articles for article (PubMed ID: 30005719)
1. Efficacy and Safety of CalliSpheres
Liu Y; Huang W; He M; Lian H; Guo Y; Huang J; Zhou J; Zhu K
Oncol Res; 2019 May; 27(5):565-573. PubMed ID: 30005719
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres
Sun J; Zhou G; Xie X; Gu W; Huang J; Zhu D; Hu W; Hou Q; Shi C; Li T; Zhang X; Ji W; Ying S; Peng Z; Zhou J; Yu Z; Ji J; Du H; Guo X; Fang J; Han J; Xu H; Sun Z; Yu W; Shao G; Wu X; Hu H; Li L; Zheng J; Luo J; Chen Y; Cao G; Hu T
Oncol Res; 2020 Feb; 28(1):75-94. PubMed ID: 31558180
[TBL] [Abstract][Full Text] [Related]
3. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
4. CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Zhang X; Zhou J; Zhu DD; Huang J; Sun JH; Li TF; Shi CS; Sun ZC; Hou QM; Peng ZY; Yu WQ; Ji JS; Gu WJ; Zhou GH; Xie XX; Guo XH; Cao GH; Yu ZH; Xu HH; Fang J; Ying SH; Hu WH; Ji WB; Han J; Wu X; Zheng JP; Luo J; Chen YT; Hu TY; Li L; Hu HJ; Du HJ; Shao GL
Clin Transl Oncol; 2019 Feb; 21(2):167-177. PubMed ID: 30003530
[TBL] [Abstract][Full Text] [Related]
5. The Comprehensive Analysis of Efficacy and Safety of CalliSpheres
Peng Z; Cao G; Hou Q; Li L; Ying S; Sun J; Zhou G; Zhou J; Zhang X; Ji W; Yu Z; Li T; Zhu D; Hu W; Ji J; Du H; Shi C; Guo X; Fang J; Han J; Gu W; Xie X; Sun Z; Xu H; Wu X; Hu T; Huang J; Hu H; Zheng J; Luo J; Chen Y; Yu W; Shao G
Oncol Res; 2020 May; 28(3):249-271. PubMed ID: 31856933
[TBL] [Abstract][Full Text] [Related]
6. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
7. Efficacy and safety profile of drug-eluting beads transarterial chemoembolization by CalliSpheres® beads in Chinese hepatocellular carcinoma patients.
Zhou GH; Han J; Sun JH; Zhang YL; Zhou TY; Nie CH; Zhu TY; Chen SQ; Wang BQ; Yu ZN; Wang HL; Chen LM; Wang WL; Zheng SS
BMC Cancer; 2018 Jun; 18(1):644. PubMed ID: 29914435
[TBL] [Abstract][Full Text] [Related]
8. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
9. Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
Peng N; Mao L; Tao Y; Xiao K; Yuan G; He S
World J Surg Oncol; 2022 Aug; 20(1):254. PubMed ID: 35941634
[TBL] [Abstract][Full Text] [Related]
10. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
11. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
12. Comparison of treatment response, survival and safety between drug-eluting bead transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in treating hepatocellular carcinoma.
Zhao C; Ma SPZCY
J BUON; 2019; 24(3):1150-1166. PubMed ID: 31424674
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CalliSpheres
Shi Z; Wang D; Kang T; Yi R; Cui L; Jiang H
Radiol Oncol; 2023 Mar; 57(1):70-79. PubMed ID: 36794998
[TBL] [Abstract][Full Text] [Related]
15. Comparison of liver function and safety in hepatocellular cancer patients treated with DEB-TACE and cTACE: a multi-center, retrospective cohort study.
Xiang H; Xiong B; Li H; Zhao C; Zhang Z; Ma C; Zheng C; Luo C; Qiu H; Yao Y; Hu H; Zhao H; Long Q; Zhou J; Chen C; Ma Y
Transl Cancer Res; 2019 Sep; 8(5):1950-1964. PubMed ID: 35116944
[TBL] [Abstract][Full Text] [Related]
16. Drug-eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety.
Li H; Wu F; Duan M; Zhang G
Medicine (Baltimore); 2019 May; 98(21):e15314. PubMed ID: 31124925
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients.
Chen C; Qiu H; Yao Y; Zhang Z; Ma C; Ma Y; Zhao C; Xiang H; Zhao H; Zheng C; Xiong B; Li H; Long Q; Zhou J; Luo C; Hu H
Clin Res Hepatol Gastroenterol; 2021 Mar; 45(2):101460. PubMed ID: 32593695
[TBL] [Abstract][Full Text] [Related]
19. Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study.
Luo J; Zheng J; Shi C; Fang J; Peng Z; Huang J; Sun J; Zhou G; Li T; Zhu D; Xu H; Hou Q; Ying S; Sun Z; Du H; Xie X; Cao G; Ji W; Han J; Gu W; Guo X; Shao G; Yu Z; Zhou J; Yu W; Zhang X; Li L; Hu H; Hu T; Wu X; Chen Y; Ji J; Hu W
Medicine (Baltimore); 2020 Mar; 99(12):e19276. PubMed ID: 32195932
[TBL] [Abstract][Full Text] [Related]
20. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
